MedTrace Logo

Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease

NCT04804618 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 650

Last updated 2022-11-15

No results posted yet for this study

Summary

This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass spectrometry (LC-MS/MS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease

Conditions

  • Alzheimer Disease, Early Onset
  • Protein; Disease

Sponsors & Collaborators

  • Guangzhou Cadre Health Management Center

    collaborator UNKNOWN

  • Guangzhou University of Traditional Chinese Medicine

    lead OTHER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04804618 on ClinicalTrials.gov